Psilocybin-Assisted Alcohol Use Disorder Outpatient Program
A structured addiction treatment service combining two supervised psilocybin sessions with motivational enhancement and cognitive-behavioral therapy, targeting AUD patients where the clinical trial cut heavy drinking days from 23.6% to 9.7% over 32 weeks.
Concept
A specialty addiction medicine service delivering psilocybin-assisted psychotherapy specifically for adults with alcohol use disorder. The treatment mirrors the protocol from [3]: two day-long psilocybin sessions (25–40 mg/70 kg, at weeks 4 and 8) embedded within 12 weeks of manualized psychotherapy combining motivational enhancement therapy and CBT, with 32 weeks of follow-up monitoring. Patients are screened to exclude major psychiatric contraindications consistent with trial exclusion criteria. Core service components include pre-treatment psychological preparation sessions, two supervised psilocybin dosing days in a supportive clinical setting, post-session integration therapy, and continuous alcohol use monitoring via timeline followback interview. The safety profile established across multiple psilocybin trials for MDD [0][4][5] and AUD [3]—consistently showing no serious adverse events under supervised conditions—makes the risk-benefit calculation favorable relative to existing pharmacotherapies with modest efficacy.
Why now
The double-blind RCT [3] demonstrated a statistically significant 13.9 percentage-point reduction in heavy drinking days over 32 weeks versus active placebo with identical therapy (P=.01). No currently approved AUD pharmacotherapy (naltrexone, acamprosate, disulfiram) achieves comparable effect sizes. With psilocybin advancing through FDA pathways and 12-month MDD follow-up data [5] showing durable effects and no drug-related serious adverse events, the evidence base is now sufficient to justify a clinical program. The US AUD population (~14.5 million) is large, systematically underserved, and increasingly open to novel modalities.
AI assessment
A clinically well-grounded AUD treatment concept with a specific RCT-validated protocol and real market need, but near-term commercial viability is severely constrained by federal Schedule I status and an immature regulatory framework.
- Evidence strength 4/5
- The AUD efficacy claim rests on one double-blind RCT (n=95, P=.01), which is real but thin as a single-trial finding; multiple independent MDD trials meaningfully corroborate the supervised-use safety profile, giving partial multi-source convergence.
- Market pull 4/5
- 14.5 million Americans with AUD, chronically underserved by existing pharmacotherapies with poor adherence and modest effect sizes, represents a large and commercially attractive addressable population — docked one point because federal Schedule I status and only two state-level therapeutic frameworks severely compress the near-term reachable market.
- Novelty & moat 3/5
- The commercial idea is a direct lift of an existing published protocol rather than a scientific or design innovation; the AUD application is less crowded than the MDD psilocybin space, but novelty is incremental rather than distinctive.
- Feasibility 2/5
- Operating legally requires either a DEA Schedule I researcher license, state-level therapeutic frameworks (currently only Oregon and Colorado), or FDA Breakthrough Therapy designation that has not yet been granted for AUD — the idea glosses over these structural barriers that make near-term clinical operation genuinely difficult rather than merely procedural.
- Wedge clarity 3/5
- Superior effect-size data versus approved pharmacotherapies is a credible differentiation argument, but the wedge depends entirely on regulatory access that doesn't yet exist at scale, and established academic medical centers already running psilocybin programs will be formidable first-movers.
- Simplicity / focus 4/5
- One indication, one well-specified protocol (two dosing days plus manualized psychotherapy), one patient population — appropriately focused without platform bloat.
Scored by AI against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity). A prior estimate to compare ideas before real-world signal arrives.
Who benefits
- Hazelden Betty Ford Foundationorganization
As the largest nonprofit addiction treatment network in the US, Hazelden Betty Ford could integrate this protocol into its existing evidence-based residential and outpatient programs, substantially improving outcomes for the AUD patients who cycle through repeated treatment episodes.
- American Addiction Centerscompany
AAC operates addiction treatment facilities nationwide and would benefit from a psilocybin-based protocol that outperforms current pharmacological standards, creating a differentiated clinical offering in a highly competitive market.
NIAAA funds AUD treatment research and would benefit from a clinical program that operationalizes the [3] trial findings, generates real-world evidence, and informs regulatory strategy for psilocybin in AUD.
- Shatterprooforganization
Shatterproof drives adoption of evidence-based addiction treatment quality standards nationwide and could champion psilocybin-assisted AUD therapy as a benchmark protocol given the strong RCT evidence.
Research it builds on
- Trial of Psilocybin versus Escitalopram for DepressionRobin Carhart‐Harris, Bruna Giribaldi, Rosalind Watts et al. · 2021 · 1378 citations
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use DisorderMichael P. Bogenschutz, Stephen Ross, Snehal Bhatt et al. · 2022 · 670 citations
- Single-Dose Psilocybin Treatment for Major Depressive DisorderCharles L. Raison, Gerard Sanacora, Joshua Woolley et al. · 2023 · 496 citations
- Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-upNatalie Gukasyan, Alan K. Davis, Frederick S. Barrett et al. · 2022 · 419 citations